Hair Relaxer Lawsuit Legal Marketing Campaigns: Spend and Targeting

The legal marketing campaigns behind the hair relaxer lawsuits are a multi-million-dollar recruitment operation, run by both law firms and specialized lead generation companies, aimed at signing up Black women diagnosed with uterine, ovarian, or endometrial cancer as plaintiffs in the federal multidistrict litigation pending in Chicago. The ads on television, Facebook, and other digital platforms are the front end of a screening pipeline that filters respondents by product use, diagnosis, and timing before their cases reach an attorney.

What the Ads Are Recruiting For

The campaigns feed In re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3060, in the U.S. District Court for the Northern District of Illinois before Judge Mary M. Rowland.¹²³

Plaintiffs allege that L’Oréal, Revlon, Strength of Nature, Namaste Laboratories, and other manufacturers sold chemical relaxers containing formaldehyde, parabens, and phthalates while marketing them as “natural,” “organic,” and “gentle,” and failed to warn that the ingredients could increase the risk of uterine, ovarian, and endometrial cancer.⁴⁵ The scientific anchor for the ad copy is a 2022 National Institute of Environmental Health Sciences study finding that women who used hair straightening products more than four times a year were roughly two and a half times more likely to develop uterine cancer than women who never used them.⁶⁷

No cases have gone to trial. The first federal bellwether trials are expected in 2027, and no global settlement has been reached, though Special Master Ellen K. Reisman is overseeing negotiations.¹⁸ That pretrial posture is precisely why the marketing spend is so heavy right now.

How Much Is Being Spent

Legal service providers spent more than $2.5 billion on 26.9 million advertisements across all media in 2024.⁹ Television alone carried about 16.4 million legal ads in 2023 at an estimated $1.2 billion, a 205% jump in spending since 2005, or roughly 45,000 legal ads broadcast daily.¹⁰

Hair relaxer litigation drew an estimated $9 million in television ad spending in 2023, in the same range as talcum powder ($9.4 million) and Roundup ($9.1 million), and well below asbestos/mesothelioma ($50.6 million) and Camp Lejeune ($46.7 million).¹⁰ Digital spending adds substantially to that figure. The top ten digital legal advertisers alone spent more than $106 million in 2023.⁹

A large share of that spending comes from companies that will never actually handle a case. Roughly one-third of the top 15 mass tort advertisers by spending are lead generators rather than law firms, meaning many of the ads viewers see are designed to collect contact information that will later be sold to attorneys.¹⁰

How the Recruitment Pipeline Works

Hair relaxer campaigns concentrate on Black and African American women between roughly 35 and 70 years old in urban areas of the Southeast, Midwest, and Northeast.¹¹ The messaging leans on the NIH study, asks about years of use, and typically prompts viewers with some version of “Did you or a loved one develop cancer after using hair relaxing or hair straightening products?”¹²

Facebook has become a particularly effective channel because the target audience is demographically specific. One agency reported costs per qualified lead on Facebook between $50 and $120, with monthly campaign budgets running $8,000 to $25,000 for a single firm.¹¹ Across mass torts more broadly, lead costs run $500 to $2,000 in moderate conditions and can exceed $3,000 during peak demand, and larger litigation groups can spend $500,000 to $2 million per month on media alone.¹³

The industry views this pretrial phase as a buying window. With no bellwether verdicts on the board, plaintiff acquisition costs are relatively lower; once verdicts land and case valuations firm up, costs per lead are expected to spike.¹¹

Between the ad and the attorney sits a lead generator. On Point Legal Leads, for example, uses a five-factor screen that covers identity verification, compliance checks, medical documentation review, structured interviews about symptoms and treatment, and evidence of product use such as receipts, salon records, or affidavits. Its baseline criteria require use of a qualifying product at least four times over a twelve-month period and a diagnosis of ovarian, uterine, or endometrial cancer.¹⁴ Mohr Marketing takes a different approach, limiting the number of firms per tort and running firm-branded campaigns instead of pooling leads; its hair relaxer criteria add at least three consecutive years of use at four or more applications per year, diagnosis within the last ten years, and age under 60 at diagnosis.¹⁵

The economics explain the volume. A meaningful national mass tort campaign typically requires $500,000 to $2 million or more in upfront marketing capital, with a return horizon of three to seven years, and third-party litigation funding, estimated at $16 billion in assets under management for 2024, backs a large portion of that spend; about 74% of funding commitments reportedly go toward legal budgets that likely include recruitment costs.¹³⁹ Not all of it pays off. One industry estimate suggests firms can waste up to 60% of their marketing budget on leads that fail internal qualification review, with a 15 to 30% return rate on unqualified leads considered normal.

Why the Targeting Is Distinctive

The hair relaxer campaigns stand apart from other mass tort recruitment because the underlying product was overwhelmingly marketed to and used by Black women. The federal master complaint alleges that approximately nine out of ten Black women have used a chemical relaxer at some point.¹² The complaint alleges manufacturers exploited “texturism,” the cultural equating of straight hair with professionalism, and points to research finding that 66% of Black and Brown girls in majority-White schools experience hair discrimination, often before age 10. Brands like “Just For Me” and “Beautiful Beginnings” were marketed to children with “gentle” claims while allegedly containing the same chemicals as adult formulas.⁴

The plaintiff-recruitment marketing replicates that demographic aim by necessity. One agency’s materials describe the “optimal claimant profile” as a Black woman aged 35 to 65 with more than 15 years of consistent use beginning in childhood or adolescence, diagnosed with uterine cancer.¹¹

What Rules Govern the Ads

Attorney advertising is constitutionally protected commercial speech, but not without limits. Under Bates v. State Bar of Arizona, ads that are “false, deceptive, or misleading” receive no First Amendment protection, and under Zauderer v. Office of Disciplinary Counsel, states may require attorneys to disclose factual information to prevent deception.¹⁶

State bar rules do most of the enforcement. Every state has adopted some form of the Model Rules of Professional Conduct, which bar communications that contain material misrepresentations or omit facts needed to avoid being misleading. The North Carolina State Bar has disciplined attorneys for claiming office locations they don’t have, experience they don’t possess, and outcomes they can’t guarantee, generally through admonitions or reprimands rather than suspension.¹⁷

Federal action has been narrower. In 2019 the FTC sent warning letters to four law firms and three lead generators over television ads that allegedly misrepresented pharmaceutical risks or falsely implied recalls. Five states have passed statutes specifically targeting legal ads soliciting pharmaceutical or medical device claimants: Texas and Tennessee in 2019, West Virginia in 2020, Indiana in 2021, and Kansas in 2022. They generally prohibit presenting ads as “medical alerts” or “public service announcements,” using government agency logos, and using the term “recall” for products not actually recalled; four of the five also require a warning against stopping medication without consulting a doctor. The Fourth Circuit upheld West Virginia’s law in Recht v. Morrissey (2022).¹⁶ Those statutes were written with drugs and devices in mind, and whether they reach hair relaxer ads is an open question.

Effects on the Litigation and the Public

Research cited by insurers suggests legal advertising increases the number of plaintiffs who file in multidistrict litigation, a pattern consistent with the hair relaxer MDL’s growth from creation in early 2023 to more than 11,500 pending cases by mid-2026.⁹

The ads also shape the environment jurors bring into court. Surveys cited by the Travelers Institute found that 90% of jurors said they would be concerned if they saw an advertisement claiming a product caused injury, and 72% believe that if lawsuits exist about a product, “there is probably truth to the claim.” The same analysis found that heavier advertising for a specific product correlates with drops in sales, market share, and defendant stock prices.¹⁰

Why the Campaigns Keep Running

No global settlement has been announced, and projected per-case values for cancer claims range from $150,000 to $750,000, though those figures are estimates rather than offers.¹ Some plaintiffs’ counsel expect defendants to seek settlement before the first bellwether trial rather than risk a large verdict, potentially as early as late 2026, with payouts not beginning until 2027.⁸ The defendants have said the claims “have neither legal nor scientific merit.”¹²

Regulatory action has stalled. The FDA’s proposed ban on formaldehyde in hair straightening products, first announced in October 2023, was delayed multiple times through 2024 and 2025 and was reportedly paused by a January 2025 executive order freezing pending federal regulations.¹⁸ The reintroduced “Safer Beauty Bill Package” in the House would ban formaldehyde, PFAS, and certain phthalates in cosmetics but has not passed. Until the courts or the regulators move, the marketing pipelines have every reason to keep buying.

1
MDL Update. MDL 3060 Hair Relaxer
2
Verus LLC. Judge Appoints MDL 3060 Leadership Team for Hair Products Litigation
3
Motley Rice. Hair Relaxer Lawsuit
4
ClassAction.org. In Re Hair Relaxer Product Liability Master Complaint
5
Bell Legal Group. The Hair Relaxer Lawsuit Explained
6
National Institutes of Health. Hair Straightening Chemicals Associated With Higher Uterine Cancer Risk
7
Journal of the National Cancer Institute. Use of Straighteners and Other Hair Products and Incident Uterine Cancer
8
Miller & Zois. Hair Relaxer Lawsuit
9
Insurance Information Institute. State of the Risk: Legal System Abuse
10
Travelers Institute. Mass Tort Legal Advertising
11
Mass Tort Ad Agency. Hair Relaxer
12
NPR. Thousands of Black Women Are Suing Chemical Relaxer Makers Over Cancer Risks
13
Lawyer Marketing Experts. Mass Tort Marketing
14
On Point Legal Leads. Chemical Hair Relaxer
15
Mohr Marketing. Hair Relaxer Lawsuit Leads
16
International Association of Defense Counsel. In Search of Mass Tort Plaintiffs
17
North Carolina State Bar. Misleading Communications: The Bad, the Ugly, and The
18
Legal Examiner Atlanta. Why the FDA Missed Another Deadline to Ban Toxic Ingredients in Hair Products